Skip Nav Destination
Article navigation
Research Articles|
November 08 2010
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Christoph Engel;
Christoph Engel
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Beatrix Versmold;
Beatrix Versmold
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Barbara Wappenschmidt;
Barbara Wappenschmidt
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Jacques Simard;
Jacques Simard
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Douglas F. Easton;
Douglas F. Easton
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Susan Peock;
Susan Peock
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Margaret Cook;
Margaret Cook
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Clare Oliver;
Clare Oliver
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Debra Frost;
Debra Frost
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Rebecca Mayes;
Rebecca Mayes
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
D. Gareth Evans;
D. Gareth Evans
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Rosalind Eeles;
Rosalind Eeles
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Joan Paterson;
Joan Paterson
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Carole Brewer;
for the Epidemiological Study of Familial Breast Cancer (EMBRACE)
Carole Brewer
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Lesley McGuffog;
Lesley McGuffog
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Antonis C. Antoniou;
Antonis C. Antoniou
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Dominique Stoppa-Lyonnet;
Dominique Stoppa-Lyonnet
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Olga M. Sinilnikova;
Olga M. Sinilnikova
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Laure Barjhoux;
Laure Barjhoux
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Marc Frenay;
Marc Frenay
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Cécile Michel;
Cécile Michel
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Dominique Leroux;
Dominique Leroux
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Helene Dreyfus;
Helene Dreyfus
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Christine Toulas;
Christine Toulas
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Laurence Gladieff;
Laurence Gladieff
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Nancy Uhrhammer;
Nancy Uhrhammer
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Yves-Jean Bignon;
Yves-Jean Bignon
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Alfons Meindl;
Alfons Meindl
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Norbert Arnold;
Norbert Arnold
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Raymonda Varon-Mateeva;
Raymonda Varon-Mateeva
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Dieter Niederacher;
Dieter Niederacher
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Sabine Preisler-Adams;
Sabine Preisler-Adams
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cancer Care Ontario, Toronto, Ontario, Canada; 51Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and 52German Cancer Research Center, Molecular Genetics of Breast Cancer (B072), Heidelberg, Germany
Search for other works by this author on:
Karin Kast;
Karin Kast
Authors' Affiliations: 1Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; 2Centre Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Centre for Integrated Oncology, University of Cologne, Cologne, Germany; 3Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Quebec City, Quebec, Canada; 4Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 5Department of Oncology, University of Cambridge, Cambridge, United Kingdom; 6Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom; 7Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; 8Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; 9Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom; 10Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 11INSERM U509, Service de Génétique Oncologique, Institut Curie, and Université Paris-Descartes, Paris, France; 12Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon/Centre Léon Bérard, Lyon, France; 13Equipe labellisée LIGUE 2008, UMR5201 Centre National de la Recherche Scientifique, Centre Léon Bérard, Université de Lyon, Lyon, France; 14Centre Antoine Lacassagne, Nice, France; 15Centre Hospitalier Universitaire, Grenoble, France; 16Institut Claudius Regaud, Toulouse, France; 17Centre Jean Perrin, Clermont-Ferrand, France; 18Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany; 19Department of Obstetrics and Gynaecology, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany; 20Institute of Human Genetics, Charite-University Medical Centre, Berlin, Germany; 21Molecular Genetics Laboratory, Department of Obstetrics and Gynaecology, University of Dusseldorf, Dusseldorf, Germany; 22Institute of Human Genetics, University of Münster, Münster, Germany; 23Department of Gynaecology and Obstetrics, Technical University, Dresden, Germany; 24Department of Gynaecology and Obstetrics, University of Ulm, Ulm, Germany; 25Institute of Human Genetics, Department of Human Genetics and Molecular Diagnostics, University of Heidelberg, Heidelberg, Germany; 26Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; 27Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 28Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 29Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden; 30Department of Clinical Genetics, Lund University, Lund, Sweden; 31Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 32Department of Oncology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 33Swedish Breast Cancer Study, Göteborg, Sweden; 34Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands; 35Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands; 36Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; 37HEereditary Breast and Ovarian cancer group Netherlands (HEBON); 38University of Pennsylvania, Philadelphia, Pennsylvania; 39Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center, Madrid, Spain, and Biomedical Network Research Centre for Rare Diseases, Barcelona, Spain; 40Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 41Molecular Diagnostics Lab, IRRP, NCSR ‘Demokritos,’ Agia Paraskevi, Greece; 42The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical center, Tel-Hashomer, Israel; 43Oncology Institute, Sheba Medical Center, Tel-Hashomer, Israel; 44Clinical Genetics Branch, National Cancer Institute, Bethesda, Maryland; 45Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland; 46Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland; 47Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota; 48Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; 49Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 50Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Department of Molecular Genetics, University of Toronto, Cance